Section 361 HCT/P Compliance Checklist for Practices

A Section 361 human cellular tissue product compliance checklist for practices provides a structured framework to audit donor screening logs, vendor FDA registration status, minimal manipulation standards, and clinical promotional material. Verifying these administrative and clinical criteria protects practice operations while ensuring that all procured biologics meet 21 CFR Part 1271 requirements for homologous use. Review the key audit steps below to streamline vendor vetting and maintain compliant supply chain workflows.

Understanding the FDA Section 361 Regulatory Framework

The FDA regulates human cells, tissues, and cellular and tissue-based products under two distinct sections of the Public Health Service (PHS) Act: Section 361 and Section 351.

Section 361 HCT/Ps are regulated solely to prevent the introduction, transmission, or spread of communicable diseases. These products do not require pre-market approval, clinical trials, or BLA (Biologics License Application) licensure, provided they satisfy four strict criteria set forth in 21 CFR 1271.10(a):

1. Minimal Manipulation: Processing does not alter the relevant biological characteristics of structural tissue, or the cellular/academic characteristics of non-structural tissue.
2. Homologous Use: The tissue performs the same basic function or functions in the recipient as in the donor.
3. No Combination: The product is not combined with another drug, device, or biological agent (with limited exceptions for water, crystalloids, or sterilizing agents).
4. Systemic Effect: The tissue does not depend on the metabolic activity of living cells for its primary function, unless it is for autologous use, allogeneic use in first- or second-degree blood relatives, or reproductive use.

If a tissue product fails any single criterion, it defaults to Section 351 regulation, categorizing it as an unapproved drug or biologic requiring a BLA. Sourcing products mistakenly marketed as 361 HCT/Ps when they are actually 351 drugs presents significant operational risk.

Section 361 HCT/P Compliance Checklist for Practices

To ensure your facility adheres strictly to 21 CFR Part 1271, use this operational checklist when evaluating vendors, receiving inventory, and managing clinical workflow.

1. Vendor Auditing & Regulatory Documentation

• [ ] FDA Registration & Listing: Confirm the manufacturer and distributor hold active FDA establishment registrations under 21 CFR 1271.
• [ ] Certificate of Analysis (CoA): Verify that every lot includes a comprehensive CoA validating safety, sterility, and endotoxin testing results.
• [ ] Donor Eligibility Records: Ensure tissue is obtained from accredited tissue banks following AATB (American Association of Tissue Banks) standards with complete donor screening for communicable diseases.
• [ ] Clarification on Manufacturing: Confirm that processing steps preserve structural matrix integrity without chemical alteration or synthetic additive inclusion.

2. Cold Chain Management & Handling Logistics

• [ ] Receiving Protocols: Log package temperature status upon arrival, verifying that dry ice or liquid nitrogen vapor shippers maintained required cryogenic temperatures.
• [ ] Dedicated Storage Equipment: Store products in calibrated ultralow-temperature freezers (-80°C) or liquid nitrogen phase storage with continuous temperature monitoring systems.
• [ ] Chain of Custody Logging: Maintain receiving, storage, and reconstitution logs matching donor lot numbers directly to specific patient records.

3. Patient Consent & Clinical Marketing Alignment

• [ ] Compliant Informed Consent: Utilize consent forms that explicitly state the product is a human tissue allograft intended for homologous structural supplementation.
• [ ] Marketing Copy Audit: Review patient-facing websites, brochures, and digital ads to remove non-compliant claims (e.g., claiming tissues cure systemic conditions, regenerate specific organs, or contain high counts of viable stem cells).
• [ ] Clinician Training Logs: Maintain documentation demonstrating that treating providers are trained in sterile handling and specific anatomical delivery protocols.

Operational vs. Clinical Perspectives on HCT/P Sourcing

Managing compliance requires alignment between administrative operations and clinical execution. Both roles view product selection through distinct, complementary lenses.

The Operational Perspective: Risk Mitigation and Inventory Health

For practice administrators and procurement managers, compliance is an operational barrier against regulatory liability and financial loss. Key priorities include:

• Vendor Due Diligence: Confirming supplier credentials prevents unexpected FDA warning letters that could disrupt supply chains or result in inventory seizures.
• Malpractice & Insurance Alignment: Ensuring that clinical procedures align with product indications so that general liability and medical malpractice policies remain valid.
• Inventory Turnover & Waste Reduction: Cryopreserved products represent significant capital investment; maintaining proper inventory flow prevents product expiration.

The Clinical Perspective: Anatomical Fit and Patient Outcomes

For pain management doctors, orthopedic specialists, and sports medicine physicians, compliance ensures safety, consistency, and therapeutic efficacy. Key priorities include:

• Homologous Application: Selecting structural tissue allografts designed specifically for localized joint, tendon, or soft tissue supplementation.
• Sterility and Endotoxin Safety: Ensuring zero contamination risk when placing tissue allografts into articular spaces or surgical sites.
• Treatment Precision: Utilizing compliant biologics alongside advanced delivery technologies to maximize tissue placement accuracy.

What This Means for Your Practice

Executing a compliance check is not a one-time event; it is an ongoing practice management requirement. Medical practices utilizing tissue allografts should take immediate steps to audit their current inventory and procedures:

1. Conduct an Immediate Vendor Review: Audit your current tissue suppliers. Request their current FDA Form 3488 (Registration of Human Cells, Tissues, and Cellular and Tissue-Based Products) and latest Certificate of Analysis for active inventory.
2. Clean Up Marketing Claims: Inspect your website and social media channels. Remove terms like "stem cell therapy" or systemic health claims when advertising Section 361 tissue allografts.
3. Update Inventory SOPs: Mandate that receiving staff log serial numbers, donor lot numbers, arrival temperatures, and expiration dates into your practice management software.
4. Review Clinical Workflow: Ensure that treating physicians document the exact anatomical site and homologous function for every applied tissue product.

Practices seeking detailed guidance on compliant regenerative workflows and tissue selection can review our operational resources and technical publications.

Secure Your Regulatory Strategy

Navigating FDA HCT/P regulations requires experienced supply chain partners who prioritize transparency, safety, and compliance. Dallas Regenerative Solutions provides fully compliant biologics, advanced delivery devices, and operational support designed for growing medical facilities.

To audit your practice’s tissue sourcing or explore compliant biological solutions, contact us to speak with a practice integration specialist.